CAS 1361227-90-8

JH-RE-06

CAS : 1361227-90-8

JH-RE-06

Formule : C₂₀H₁₆Cl₃N₃O₄

Degré de pureté : ≥98%

Masse moléculaire : 468.72

Ref: 54-BUP04266

JH-RE-06

CAS : 1361227-90-8

JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing the recruitment of mutagenic POLζ.

Formule : C₂₀H₁₆Cl₃N₃O₄

Degré de pureté : 99.29%

Couleur et forme : Solid

Masse moléculaire : 468.72

Ref: TM-T15611

JH-RE-06

CAS : 1361227-90-8

8-Chloro-2-((2,4-dichlorophenyl)amino)-3-(3-methylbutanoyl)-5-nitroquinolin-4(1H)-one

Formule : C₂₀H₁₆Cl₃N₃O₄

Degré de pureté : 99%

Masse moléculaire : 468.72

Ref: IN-DG01133423

JH-RE-06

CAS : 1361227-90-8

Degré de pureté : 98%

Masse moléculaire : 467.02

Ref: 10-F554609

JH-RE-06

CAS : 1361227-90-8

JH-RE-06 is a drug that can be used to treat cancer. It is an inhibitor of the enzyme topoisomerase II, which is needed for replication and transcription. The death of cancer cells is due to the inhibition of DNA replication and transcription by JH-RE-06. JH-RE-06 is also mutagenic and cisplatin treatment has been shown to increase its potency. This drug has been shown to have high specificity, with only a small number of cells showing resistance. JH-RE-06 can be used as part of a therapy regimen that includes cisplatin, which may be used in combination with other drugs in order to improve efficacy. The discovery of new hallmarks for cancer cells, such as the ability to sense light or respond to changes in acidity, may lead to better ways of monitoring cancer cells and detecting tumor formation at an early stage.

Formule : C₂₀H₁₆Cl₃N₃O₄

Degré de pureté : Min. 95%

Masse moléculaire : 468.72 g/mol

Ref: 3D-LEC22790